Skip to main content

2023 IKCS: North America Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Therapeutics (Local- Primary and Metastasis)

Therapeutics (Local- Primary and Metastasis)

Type here to filter the list

4: LITESPARK-013: Randomized Phase 2 Study of Two Doses of Belzutifan in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Favorite
58: Subgroup analyses of KEYNOTE-564: Adjuvant pembrolizumab for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage

Favorite
71: STELLAR-304: A phase 3 study of zanzalintinib (XL092) plus nivolumab versus sunitinib in non–clear cell renal cell carcinoma (nccRCC)

Favorite